New Zealand vs Norway: Hepatitis B surface antigen (HBsAg) prevalence
New Zealand
0.0%
in 2024
Norway
0.0%
in 2024
New Zealand rank
132nd
Norway rank
132nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- New Zealand
- Norway
How they compare
New Zealand currently reports 0.0% against 0.0% in Norway, a difference of 0.0%.
Across all 10 years both countries report, Norway has been ahead every year.
New Zealand ranks 132nd and Norway ranks 132nd of 194 countries.
Norway has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | New Zealand | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Norway |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, New Zealand or Norway?
- New Zealand, at 0.0% against 0.0% in Norway as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between New Zealand and Norway?
- 0.0%, with New Zealand ahead.
- How many years of comparable data are there for New Zealand and Norway?
- 10 years are reported by both, from 2015 to 2024.
- How do New Zealand and Norway rank globally for hepatitis b surface antigen (hbsag) prevalence?
- New Zealand ranks 132nd and Norway ranks 132nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.